Patents Assigned to Aptinyx, Inc.
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11578072
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders as well as other disorders.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: February 14, 2023
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11530223
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: December 20, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11512051
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: November 29, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA modulators and methods of using same
    Patent number: 11427585
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: August 30, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11376250
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: July 5, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA modulators and methods of using same
    Patent number: 11370790
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: June 28, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11299495
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: April 12, 2022
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11077094
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: August 3, 2021
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11028095
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: June 8, 2021
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10961189
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: March 30, 2021
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10918637
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: February 16, 2021
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10441571
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: October 15, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10441572
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: October 15, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME
    Publication number: 20190194200
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: August 1, 2017
    Publication date: June 27, 2019
    Applicant: Aptinyx Inc.
    Inventor: M. Amin KHAN
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10316041
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: June 11, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10273239
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: April 30, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10253032
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: April 9, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10196401
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: February 5, 2019
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10195179
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: February 5, 2019
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA modulators and methods of using same
    Patent number: 10150769
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: December 11, 2018
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan